Has Jonathan Cagle received payments from drug or device companies?

Yes. Drug and device makers reported $1,464 in general payments to Jonathan Cagle across 61 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jonathan Cagle did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jonathan Cagle come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jonathan Cagle

Family · Slidell, LANPI 1659963882

Payments from drug & device makers

$1,464in general payments, 2019–2025

Across 61 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$486
AbbVie$287
Lundbeck LLC$220
Lilly USA, LLC$112
Axsome Therapeutics, Inc.$80
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$59
plus $221 from 8 others

What the payments were for

Food & beverage$1,464100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	10	$486
AbbVie	15	$287
Lundbeck LLC	12	$220
Lilly USA, LLC	6	$112
Axsome Therapeutics, Inc.	3	$80
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	3	$59
GSK	2	$42
Corium, LLC	2	$41
Idorsia Pharmaceuticals US Inc	2	$33
Otsuka America Pharmaceutical, Inc.	2	$28
Takeda Pharmaceuticals U.S.A., Inc.	1	$23
CSL Behring	1	$23
Indivior Inc.	1	$17
Paratek Pharmaceuticals, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,464 in reported general payments places this provider in the 70th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana →

Medicare billing

Part B allowed, 2024

$27,542

Medicare patients

193

Services billed

736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	24	$30,254
JardianceEmpagliflozin	31	$27,713
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	36	$24,009
SymbicortBudesonide/Formoterol Fumarate	14	$3,360
DilantinPhenytoin Sodium Extended	13	$2,410
Albuterol Sulfate HfaAlbuterol Sulfate	48	$1,143
Fluticasone Propionate	120	$812
LantusInsulin Glargine,hum.Rec.Anlog	13	$793
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	71	$718
Atorvastatin Calcium	76	$656
Levothyroxine Sodium	64	$549
Methylprednisolone	106	$543
Ropinirole Hcl	29	$534
Doxycycline Hyclate	101	$515
Pregabalin	18	$508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GSKTrelegy Ellipta	$42	$24,00936 claims
AstraZenecaSymbicort	$486	$3,36014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,610 family providers in Louisiana.